Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2021-11-30
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Using Mini Program for Self-management VS Conventional Pharmaceutical Care for Cancer Pain
NCT04844645
A Randomized Controlled Trial of a Web-based Platform for Cancer Pain Management
NCT06663956
Pain Management in Cancer Patients Using a Mobile Application
NCT02069743
STAMP+CBT mHealth for Cancer Pain
NCT05403801
Ambulatory Cancer Pain Management: A Feasibility Study
NCT00507351
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To design, construct, and test the mini program in patients managing cancer pain, evaluate the total remission rate of pain and the improvement in medicine compliance to improve pain management for cancer pain patients, and assess patient acceptance of the mini program.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
a mini program trial group
Pharmacists conducted a standardized education session to teach the participants how to operate the mobile phone, use mini program, assess pain. The participants in the trial group were asked to complete initial and final pain assessment questionnaires and Medication compliance on the mobile phones provided to them. Participants were encouraged to use mini program as much as possible to record their pain status.
mini program
To design, construct, and test the mini program in patients managing cancer pain
a control group
The control group received conventional pharmaceutical care. Initial and final pain and Medication compliance data were collected. Before the patient was discharged from the hospital, the clinical pharmacist conducted detailed medication education (including medication methods, prevention and treatment of adverse reactions, and precautions) and asked the patient to attempt to maintain a paper version of the pain diary.
conventional pharmaceutical care
Regular education includes medication guidance from doctors, nurses and pharmacists.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mini program
To design, construct, and test the mini program in patients managing cancer pain
conventional pharmaceutical care
Regular education includes medication guidance from doctors, nurses and pharmacists.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be able to read Chinese and use a mobile phone;
* Histologically or cytologically confirmed solid tumor;
* Diagnosed chronic cancer pain
* Could understand the study process and evaluation, agreed to participate in the trial, and signed the informed consent form.
Exclusion Criteria
* Incompetence;
* Inability to complete the pain assessment;
* Participation in any other therapies or other study protocols that may have an impact on pain intensity, which were the main outcomes of this study.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fujian Cancer Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FJZLYX002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.